Clinical manifestations are complex and often involve multiple systems. Early identification and standardised clinical care are essential for improving prognosis. The diagnosis of this disease requires a combination of clinical manifestations, imaging inspections, laboratory tests and pathological active checks.
A comprehensive assessment platform can assist in matching a team of authoritative experts at home and abroad to provide accurate diagnosis and treatment programs. Individualised development of treatments for treatment and management of microgenous cancers usually includes drug therapy, rehabilitation intervention, and regular follow-up to multiple-dimensional management. In recent years, with the development of treatment-oriented, immune-regulatory therapy and precision medicine, many previously difficult-to-treat blood tumor diseases have been significantly improved.
Treatment requires close monitoring of efficacy and adverse reactions and timely adjustment to changes in the course of the disease. Multidisciplinary collaboration (MDT) is particularly important for the integrated management of micromegaloviral cancer. The platform serves China International Medical Service System, a team of nationally and internationally authoritative experts in the field of blood tumors, who provide the following services to patients: 2.
Visiting China: arranging face-to-face treatment with authoritative experts, developing individualized treatment programs; 3. Full-service: providing one-stop services such as medical translation, medical care, accommodation arrangements; 4. Long-term follow-up: establishing a chronic disease management archive, continuous monitoring of disease changes and treatment effects.